SecBot

SecBot
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001974640

APGE

Apogee Therapeutics, Inc.
—
Market cap$10.2B
ConsensusSell
12-mo target$134.62 (-0.3%)
▼ Bearish
Analyst conviction 3/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)32 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on APGE right now — valuation, ownership and activity at a glance.
Market Cap
$10.2B
Cap Size
Large Cap
Analyst Consensus
Sell (29%)
Inst. Holders
50 funds
Inst. Value
$5.1B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $737.9K sell
Insider Net $
-$737.9K
SEC Reports
20
Press Releases
8
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 SEC
Apogee Therapeutics has filed a Form 15-12G to terminate its SEC registration and suspend reporting obligations, effecti
15-12G — Impact 4/10
Sep 4, 2026 listing_status
Delisted: APGE — removed from the Nasdaq symbol directory
Apogee Therapeutics, Inc. - Common Stock
Sep 3, 2026 SEC
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Sh
25-NSE — Impact 8/10
Sep 3, 2026 SEC
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Sh
8-K — Impact 8/10
Sep 3, 2026 Insider
Fairmount Funds Management LLC disposed of 6,743,321 shares
Director
Sep 3, 2026 Insider
Fairmount Funds Management LLC disposed of 10,370 shares
Director
Sep 3, 2026 Insider
Fairmount Funds Management LLC disposed of 340,855 shares
Director
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
5,507,032 shares ($730.9M)
Analyst ratings buy % -69.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Sell 29% rate it Buy or better · 21 analysts
Strong Buy 2 10% Buy 4 19% Hold 15 71% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Aug 13, 2026Truist SecuritiesMAINTAINHold 55%
Aug 12, 2026BTIGDOWNGRADENeutral 53%
Jun 24, 2026StifelDOWNGRADEHold 54%
Jun 24, 2026TD CowenDOWNGRADEHold 56%
Jun 24, 2026GuggenheimDOWNGRADENeutral 52%
Jun 24, 2026MizuhoDOWNGRADENeutral 52%
Jun 23, 2026Deutsche BankDOWNGRADEHold 58%
Jun 23, 2026CitigroupDOWNGRADENeutral 55%
Jun 23, 2026RBC CapitalMAINTAINSector Perform 55%
Jun 23, 2026UBSDOWNGRADENeutral 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202624150029%
Aug 1, 202634140033%
Jul 1, 202634140033%
Jun 1, 2026101050080%
May 1, 202610940083%
Apr 1, 202610940083%
Mar 1, 202610930086%
Feb 1, 202610930086%
Price targets
Where 5 covering analysts think APGE trades over the next 12 months.
$134.62 -0.3% upside Hold
Current$135.07 Low$133.00 Median$135.00 High$135.11 5 analysts
$133.00$135.11
Analyst rating Hold· 2.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 11 bullish, 0 bearish, 1 mixed, 8 neutral · avg impact 5.5/10.Plus 8 press releases.
NEUTRAL15-12G4/10
Apogee Therapeutics has filed a Form 15-12G to terminate its SEC registration and suspend reporting
Sep 14, 2026
BULLISH25-NSE8/10
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximate
Sep 3, 2026
BULLISH8-K8/10
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximate
Sep 3, 2026
BULLISH8-K7/10
Apogee Therapeutics stockholders voted overwhelmingly to approve the $135.11/share all-cash acquisit
Aug 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 4, 2026
listing_status
Delisted: APGE — removed from the Nasdaq symbol directory
Apogee Therapeutics, Inc. - Common Stock
Sep 4, 2026
trading_halt
Halt Resumed: APGE — trading resumed after D (Security Deletion)
Halted 2026-09-02T23:50:00.000Z | Resumed 2026-09-04T04:00:01.000Z
Sep 2, 2026
trading_halt
Trading Halt: APGE — D (Security Deletion)
Apogee Therapeutics, Inc. | Market: NASDAQ | Code: D — Security Deletion
Sep 2, 2026
trading_halt
Trading Halt: APGE — T12 (Additional Information Requested)
Apogee Therapeutics, Inc. | Market: NASDAQ | Code: T12 — Additional Information Requested
Aug 10, 2026
earnings
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology po
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-1.25$-1.27–$-1.23-12.6%-8.2%2↑ 3↓$0.0B2
Next Q$-1.37$-1.40–$-1.34-33.0%-10.7%2↑ 3↓$0.0B2
Current FY$-4.86$-4.93–$-4.79-15.2%-10.1%1↑ 3↓$0.0B2
Next FY$-5.20$-5.87–$-4.36-6.9%-0.1%2↑ 3↓$0.0B6
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-1.250—
7d ago$-1.191-0.059
30d ago$-1.155-0.095
60d ago$-1.155-0.095
90d ago$-1.167-0.083
Institutional ownership
Which big funds own APGE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $5.1B total value (38,928,502 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, FMR. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.5,507,032$730.9M14.2%ADD +34.8%
VANGUARD CAPITAL MANAGEMENT LLC2,572,119$341.4M6.7%—
FMR LLC2,493,137$330.9M6.5%TRIM -73.1%
STATE STREET CORP2,297,743$305.0M5.9%—
DRIEHAUS CAPITAL MANAGEMENT LLC1,740,101$231.0M4.5%—
GOLDMAN SACHS GROUP INC1,693,341$224.8M4.4%DOUBLED +159.5%
BALYASNY ASSET MANAGEMENT L.P.1,665,102$221.0M4.3%DOUBLED +279.6%
VANGUARD PORTFOLIO MANAGEMENT LLC1,528,750$202.9M4.0%DOUBLED +285.7%
MILLENNIUM MANAGEMENT LLC1,491,404$198.0M3.9%DOUBLED +1510.7%
Pentwater Capital Management LP1,425,000$189.1M3.7%NEW
Recent position changes
FundActionPrevCurrentChangeValue
BlackRock, Inc.ADD4,085,6515,507,032+34.8%$730.9M
FMR LLCTRIM9,262,2912,493,137-73.1%$330.9M
GOLDMAN SACHS GROUP INCDOUBLED652,5901,693,341+159.5%$224.8M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED438,6541,665,102+279.6%$221.0M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED396,3301,528,750+285.7%$202.9M
MILLENNIUM MANAGEMENT LLCDOUBLED92,5921,491,404+1510.7%$198.0M
Pentwater Capital Management LPNEW—1,425,000—$189.1M
MORGAN STANLEYDOUBLED595,0321,421,681+138.9%$188.7M
BANK OF AMERICA CORP /DE/ADD900,8711,126,139+25.0%$149.5M
Qube Research & Technologies LtdNEW—659,678—$87.6M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$737.9K — $0.00 bought, $737.9K sold.
DateInsiderTitleTypeSharesPriceValue
Sep 3, 2026Fairmount Funds Management LLCDirectorD6,743,321——
Sep 3, 2026Fairmount Funds Management LLCDirectorD10,370——
Sep 3, 2026Fairmount Funds Management LLCDirectorD340,855——
Sep 3, 2026Fairmount Funds Management LLCDirectorD51,166——
Sep 3, 2026Fairmount Funds Management LLCDirectorD7,657——
Sep 3, 2026Fairmount Funds Management LLCDirectorD47,758——
Sep 3, 2026Fairmount Funds Management LLCDirectorD14,461——
Sep 3, 2026JONES WILLIAM A JRDirectorD34,824——
Sep 3, 2026JONES WILLIAM A JRDirectorD14,461——
Sep 3, 2026JONES WILLIAM A JRDirectorD7,657——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for APGE.
Shares short
4,203,052
Settlement Aug 31, 2026
Change vs prior
-1.6%
Semi-monthly cycle
Days to cover
3.5
At avg daily volume
Of shares outstanding
≈5.5%
Estimate — not % of float
HaltedCodeReasonStatus
Sep 2, 2026DDeletionResumed
Sep 2, 2026T12Info RequestedNot resumed
All APGE filing & press-release reports (31)